Fortress Biotech (NASDAQ:FBIO – Get Free Report)‘s stock had its “buy” rating restated by stock analysts at Roth Mkm in a report issued on Tuesday,Benzinga reports. They presently have a $16.00 price target on the biopharmaceutical company’s stock, up from their previous price target of $15.00.
FBIO has been the topic of several other reports. StockNews.com cut Fortress Biotech from a “hold” rating to a “sell” rating in a report on Friday, November 15th. HC Wainwright boosted their target price on shares of Fortress Biotech from $24.00 to $26.00 and gave the stock a “buy” rating in a report on Monday, November 18th. One analyst has rated the stock with a sell rating and four have given a buy rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $15.67.
Check Out Our Latest Stock Analysis on FBIO
Fortress Biotech Stock Performance
Institutional Trading of Fortress Biotech
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Wolverine Trading LLC acquired a new position in shares of Fortress Biotech in the 4th quarter worth approximately $26,000. Weaver Consulting Group grew its holdings in Fortress Biotech by 33.0% during the 4th quarter. Weaver Consulting Group now owns 22,998 shares of the biopharmaceutical company’s stock worth $47,000 after acquiring an additional 5,700 shares during the period. XTX Topco Ltd bought a new position in shares of Fortress Biotech in the 4th quarter worth about $62,000. Integrated Wealth Concepts LLC lifted its stake in shares of Fortress Biotech by 68.2% in the 3rd quarter. Integrated Wealth Concepts LLC now owns 46,100 shares of the biopharmaceutical company’s stock valued at $67,000 after purchasing an additional 18,700 shares during the period. Finally, Jane Street Group LLC acquired a new position in shares of Fortress Biotech in the 4th quarter valued at about $69,000. Institutional investors and hedge funds own 96.51% of the company’s stock.
About Fortress Biotech
Fortress Biotech, Inc, a biopharmaceutical company, develops dermatology, pharmaceutical, and biotechnology products in the United States. The company markets dermatology products, such as Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane capsules for severe recalcitrant nodular acne; Amzeeq for severe acne vulgaris; Zilxi, a topical foam; Exelderm cream and solution for topical use; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Luxamend; sulconazole nitrate cream and solution for tinea cruris and tinea corporis; and doxycycline hyclate tablet.
Further Reading
- Five stocks we like better than Fortress Biotech
- Health Care Stocks Explained: Why You Might Want to Invest
- U.S. Stocks Sink, Foreign Markets Soar: 3 ETFs to Ride the Wave
- Why Invest in 5G? How to Invest in 5G Stocks
- Joby Aviation: From Prototype to Profitability
- How to Use the MarketBeat Excel Dividend Calculator
- Marvell’s 40% Drop Presents a Compelling Buying Opportunity
Receive News & Ratings for Fortress Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fortress Biotech and related companies with MarketBeat.com's FREE daily email newsletter.